Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 2/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | UNG | P13051 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4210353 | 0.83 | HPGD (0.48) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL69064 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL2406839 | 0.83 | CYP1A2 (0.76) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL29380400 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL31383422 | 0.83 | CYP1A2 (0.76) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL27474390 | 0.82 | PARP1 (0.57) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL8712530 | 0.81 | HSD17B10 (0.73) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL2801844 | 0.79 | CYP1A2 (0.84) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL16302528 | 0.79 | CYP1A2 (0.70) | CYP1A2CYP2C9HPGDHSD17B10APEX1 | |
| SCHEMBL659462 | 0.79 | HSD17B10 (0.70) | CYP1A2CYP2C9HPGDHSD17B10APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326976-B2 | Carbamate derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-9326976-B2 | Carbamate derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20150352090-A1 | CARBAMATE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| US-20150352090-A1 | CARBAMATE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| US-5847061-A | Process for producing polymers having terminal functional group which may be protected | KURARAY CO., LTD. (JP) | 1998-12-08 | — | — | US | disclosed |
| EP-0704460-B1 | PROCESS FOR PRODUCING POLYMER TERMINATED WITH OPTIONALLY PROTECTED FUNCTIONAL GROUP | KURARAY CO (JP) | 1998-11-04 | — | — | EP | disclosed |
| EP-0704460-A1 | PROCESS FOR PRODUCING POLYMER TERMINATED WITH OPTIONALLY PROTECTED FUNCTIONAL GROUP | KURARAY CO., LTD. (JP) | 1996-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352090-A1 | CARBAMATE DERIVATIVES | CHRM3, PDE4A, PDE4B | CYP1A2 501/4885CYP2C9 561/4885HPGD 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.